文献速递妇科产科

既往乳腺癌及他莫昔芬暴露不影响子宫乳头状浆液性癌患者的结局

Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.
PubMed 文献 · Gynecol Oncol · 2017-01-03

在两所学术机构1997年1月至2012年7月诊断的323例子宫乳头状浆液性癌(UPSC)患者中,46例(14%)有乳腺癌病史,其中15例(33%)有他莫昔芬使用史。有乳腺癌病史者较无乳腺癌病史者年龄更大(中位年龄72岁 vs 68岁,p=0.004),但无进展生存期(PFS)和总生存期(OS)无显著差异,他莫昔芬暴露与否亦无差异。

要点

  • UPSC患者中14%(46/323)有乳腺癌病史,其中33%(15/46)曾用他莫昔芬。
  • 有乳腺癌病史者中位年龄72岁 vs 无乳腺癌病史者68岁(p=0.004)。
  • 有乳腺癌病史者与无乳腺癌病史者的PFS和OS均无显著差异(p=0.64和p=0.73)。

核心结论

  • 有乳腺癌病史的UPSC患者与无乳腺癌病史者的PFS和OS无差异。
  • 在子宫内膜癌诊断前使用他莫昔芬者未显示OS或PFS的显著差异。

研究设计与样本

  • 两所学术机构1997年1月至2012年7月诊断的UPSC女性数据收集。
  • 共323例UPSC患者,分为有乳腺癌病史(UPSCBR+,46例,14%)和无乳腺癌病史(UPSCBR-)两组。
  • UPSCBR+组中15例(33%)有他莫昔芬使用史。
  • 采用Cox回归模型分析PFS和OS与所选协变量的关联。

主要发现

  • UPSCBR+患者较UPSCBR-患者年龄更大(中位年龄72岁 vs 68岁,p=0.004)。
  • UPSCBR+与UPSCBR-的PFS无显著差异(p=0.64),OS无显著差异(p=0.73)。
  • 控制年龄后,UPSCBR+与UPSCBR-的PFS无显著差异(p=0.15),OS无显著差异(p=0.48)。
  • UPSCBR+组内,有他莫昔芬暴露与无他莫昔芬暴露的PFS无差异(p=0.98),OS无差异(p=0.94)。

临床怎么用

  • 作者认为这些发现对咨询有启示,应对面临第二癌症诊断的女性具有鼓励作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate progression-free survival (PFS) and overall survival (OS) outcomes in women diagnosed with uterine papillary serous carcinoma (UPSC) who have had (UPSCBR+) or have not had (UPSCBR-) an antecedent history of breast cancer and to correlate their outcomes to prior tamoxifen exposure. METHODS: Data were collected for women diagnosed with UPSC at two academic institutions between January 1997 and July 2012. Patient demographics, tumor histology, stage, and treatments were recorded. Patients were divided into two groups: those with and without a personal history of breast cancer. Within the UPSCBR+ cohort, we identified those with a history of tamoxifen use. Cox regression modeling was used to explore associations between selected covariates of interest and the time-to-event outcomes of PFS and OS. RESULTS: Of 323 patients with UPSC, 46 (14%) were UPSCBR+. Of these, 15 (33%) had a history of tamoxifen use. UPSCBR+ patients were older than UPSCBR- (median years, 72 vs. 68, p=0.004). UPSCBR+ women showed no significant difference in PFS or OS compared to UPSCBR- (p=0.64 and p=0.73 respectively), even after controlling for age (p=0.15 and p=0.48 respectively). Within the UPSCBR+ cohort, there was no difference in PFS or OS with or without tamoxifen exposure (p=0.98 and p=0.94 respectively). CONCLUSIONS: There was no difference in PFS or OS between the UPSCBR+ and UPSCBR- cohorts. We did not demonstrate significant OS or PFS differences in women who took tamoxifen prior to their endometrial cancer diagnosis. These findings have implications for counseling, and should be encouraging to women who are facing their second cancer diagnosis.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Pierce SR, Stine JE, Gehrig PA, et al. Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. Gynecol Oncol. 2017. PMID: 28062116. doi:10.1016/j.ygyno.2016.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。